Dr. Babak Tousi, M.D.
Geriatric Medicine (Geriatric Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 267
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Geriatric Medicine (Internal Medicine) Physician primary
OH license 35083489
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Hillcrest Hospital Mayfield Heights, OH
- Akron General Medical Center Akron, OH
- Fairview Hospital Cleveland, OH
- Cleveland Clinic Avon Hospital Avon, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 267
- Services billed
- 510
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 182 | 161 |
| New patient office or other outpatient visit, 60-74 minutes | 97 | 97 |
| Established patient office or other outpatient visit, 30-39 minutes | 96 | 85 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Cleveland, OH | 493 |
| Memantine Hcl Other prescribers in Cleveland, OH | 185 |
| Sertraline Hcl Other prescribers in Cleveland, OH | 167 |
| Duloxetine Hcl Other prescribers in Cleveland, OH | 37 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Cleveland, OH | 33 |
| Mirtazapine Other prescribers in Cleveland, OH | 30 |
| Buspirone Hcl Other prescribers in Cleveland, OH | 30 |
| Quetiapine Fumarate Other prescribers in Cleveland, OH | 27 |
| Escitalopram Oxalate Other prescribers in Cleveland, OH | 26 |
| Rivastigmine (rivastigmine tartrate) Other prescribers in Cleveland, OH | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 27 payments worth $54,024 in total to this clinician.
| Eisai Inc. | $18,934 |
|---|---|
| Novo Nordisk Inc | $18,154 |
| Novo Nordisk As | $9,626 |
| Biogen, Inc. | $7,022 |
| Lilly USA, LLC | $185 |
| Teva Pharmaceuticals USA, Inc. | $103 |
| Consulting Fee | $35,145 |
|---|---|
| Travel and Lodging | $15,202 |
| Compensation for services other than consulting (speaking, faculty) | $2,455 |
| Food and Beverage | $1,222 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Jun 25, 2025 | Consulting Fee | $9,800 |
| Novo Nordisk Inc Feb 26, 2025 | Travel and Lodging travel to Nové Město, Czech Republic · in-kind | $9,716 |
| Novo Nordisk As Jul 27, 2025 | Consulting Fee | $8,584 |
| Novo Nordisk Inc Feb 26, 2025 | Consulting Fee | $7,494 |
| Eisai Inc. May 1, 2025 | Consulting Fee Leqembi · Neurology | $4,700 |
| Eisai Inc. May 1, 2025 | Travel and Lodging Leqembi · Neurology · travel to San Diego, CA | $3,055 |
| Biogen, Inc. May 15, 2025 | Consulting Fee | $2,569 |
| Biogen, Inc. Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,455 |
| Biogen, Inc. Apr 3, 2025 | Consulting Fee | $1,998 |
| Eisai Inc. May 1, 2025 | Travel and Lodging Leqembi · Neurology · travel to San Diego, CA | $832 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk As Jul 27, 2025 | Consulting Fee | $8,584 |
| Novo Nordisk As Jul 27, 2025 | Travel and Lodging travel to Toronto, Canada · in-kind | $786 |
| Novo Nordisk As Jul 27, 2025 | Travel and Lodging travel to Toronto, Canada · in-kind | $131 |
| Biogen, Inc. Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,455 |
| Eisai Inc. Jul 2, 2025 | Travel and Lodging travel to Chicago, IL | $125 |
| Eisai Inc. Jun 25, 2025 | Consulting Fee | $9,800 |
| Biogen, Inc. May 15, 2025 | Consulting Fee | $2,569 |
| Eisai Inc. May 1, 2025 | Consulting Fee Leqembi · Neurology | $4,700 |
| Eisai Inc. May 1, 2025 | Travel and Lodging Leqembi · Neurology · travel to San Diego, CA | $3,055 |
| Eisai Inc. May 1, 2025 | Travel and Lodging Leqembi · Neurology · travel to San Diego, CA | $832 |
| Biogen, Inc. Apr 3, 2025 | Consulting Fee | $1,998 |
| Novo Nordisk Inc Feb 26, 2025 | Travel and Lodging travel to Nové Město, Czech Republic · in-kind | $9,716 |
| Novo Nordisk Inc Feb 26, 2025 | Consulting Fee | $7,494 |
| Novo Nordisk Inc Feb 26, 2025 | Travel and Lodging travel to Nové Město, Czech Republic · in-kind | $488 |
| Novo Nordisk Inc Feb 26, 2025 | Travel and Lodging travel to Nové Město, Czech Republic · in-kind | $70.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $1,164,327 in research payments for these studies, mostly to the institutions running them.
- A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) an…
Eisai Inc. - A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease
Janssen Research & Development, LLC - A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc. - Study name not reported
Novo Nordisk As - Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205
Biogen, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.